Home » Newsletters » BioWorld Science

BioWorld Science

April 17, 2001

View Archived Issues

Phase III Oxygent trial shows benefit in reducing and avoiding blood transfusions

Galenica and UAB form research agreement for HSV vaccine

Titan's CeaVac and TriAb studied in combination with radiation therapy for NSCLC

Boehringer Ingelheim and Pfizer to comarket Spiriva for COPD

Second-generation antisense drug shows promise in phase I

Nikken Chemicals investigates dihydropyridines for overcoming MDR

Noncytotoxic taxanes designed as potent MDR reversal agents

Orally active combretastatin A-4 analogues presented at ACS meeting by Abbott researchers

Micro Therapeutics cleared to commence separate pivotal trial of Onyx LES for AVMs

TX-1991, a new DNA-intercalating anticancer agent and radiosensitizer

Abbott identifies antimitotic agents retaining activity in MDR tumors

Millennium and BZL establish agreement for antibody therapies targeting PSMA

Berlex/Schering AG discover highly potent nonamidine factor Xa inhibitor with oral bioavailability

Antitumor and antiangiogenic effects of TNP-470 in models of bladder cancer

Effects of TAK-637 on bladder function in cats detailed at Japanese scientific meeting

Maxim's Ceplene to be included in DITTO-HCV study

MMP inhibitor demonstrates antimetastatic effects following oral administration in murine model

Keryx provides concise report of clinical progress

Vardenafil significantly improves ability to successfully complete intercourse in diverse population

Cyclacel and AstraZeneca form collaboration based on anticancer drug target

The future role of rabeprazole in the treatment of acid-related disorders

New prostaglandin derivatives from Taisho useful for nephropathy and cardiovascular disorders

Aventis presents new inhibitors of coagulation factors

Pfizer's somatostatin antagonists enhance GH secretion

Agents for herpesvirus infections in development at AHP

Recent patent describes Molecumetics' reverse-turn mimetics and their use

Maxia describes series useful in diabetes and hyperproliferative disorders

Broad-spectrum antibacterial activity reported for new FabH inhibitors